💸 The Tape

Green Thumb Industries (CSE: GTII) (OTCQX: GTBIF) renewed its share repurchase program Monday for another 12 months with up to $50 million available, starting September 23 and running through September 22, 2027. It's the fourth consecutive year the board has authorized a buyback, and the cumulative tally is now hard to ignore: since the first program launched in September 2023, Green Thumb has retired roughly 29.5 million shares for $203.4 million, more than $80 million of it in 2026 alone.

Ben Kovler's framing was characteristically plain. Renewing the program, he said, gives the company flexibility to keep buying stock "when conditions present an attractive opportunity" while it weighs organic investment and M&A. The release notes Green Thumb doesn't expect to borrow to fund purchases, isn't obligated to buy a single share, and will cancel everything it does buy. That's the language of a company with $284 million of cash against $283 million of debt and the operating cash flow to keep both sides of that ledger stable while shrinking the denominator.

What $200 million of buybacks actually did

The arithmetic matters because cannabis investors have spent a decade watching share counts go the other way. Green Thumb's diluted count peaked around 240 million; retiring 29.5 million shares is a 12% reduction of the float, done at an average price of roughly $6.90 — a range that, depending on when you mark it, has been at or below where the stock trades today. Every dollar of RYTHM and Dogwalkers margin now gets divided among fewer owners, and the company bought most of those shares during the two years when the sector was priced for terminal decline.

Compare that to the alternative uses of capital available to a Chicago MSO in 2024 and 2025: overpaying for stores in capped states, or sitting on cash at a bank that charged it a premium for the privilege. Kovler chose neither, and the buyback has been the single most shareholder-accretive capital decision any U.S. operator has made in this cycle. The renewed $50 million is an option, not a promise, but the history says it gets used.

The peers are following

Green Thumb was the first large MSO to buy back stock in size. It's no longer alone, and the pattern says something about where the healthiest operators think the sector is.

Trulieve authorized a $50 million repurchase in June, capped at 8.5 million subordinate voting shares — 5% of the float — running through June 2027. The timing was deliberate: the program was announced the same week Trulieve completed its medical-only restructuring and listed on the NYSE, with net cash on the balance sheet and a 36% EBITDA margin. Kim Rivers called it a tool to deliver value "when market conditions present a compelling opportunity," which is the same sentence Kovler has been saying for three years.

Verano launched a normal course issuer bid in April and, after its 1-for-5 reverse split in June, amended it to cover up to 3.64 million post-split shares — roughly 5% of the new count. Verano's balance sheet is thinner than Green Thumb's or Trulieve's, so the bid is smaller and more conditional, but the intent is identical: buy back a stock that management believes is mispriced, tidy up the capitalization, and prepare for a U.S. exchange application.

North of the border, High Tide didn't authorize a corporate buyback but did the retail-investor version: Raj Grover and a group of officers and directors bought roughly 91,000 shares in the open market in May at $3.39, ahead of the record quarter the company just reported.

Notably absent from the list is Curaleaf, which is spending its capital and its currency on a hostile bid for Aurora rather than on its own shares — a reasonable choice for a company carrying $612 million of debt, and a reminder that buybacks are a privilege of the unlevered.

What it signifies

Three things.

First, the operators with the best balance sheets believe their equity is cheap relative to their cash flow, and they are willing to say so with money rather than adjectives. In an industry that has historically raised capital at any price, the largest, most profitable companies are now returning it. That is what maturity looks like.

Second, buybacks are pre-uplisting hygiene. Every company on this list is either on a U.S. exchange (Trulieve), preparing to apply (Verano), or has said it expects to list once rescheduling clears (Green Thumb, which has been the loudest about the SEC and Nasdaq for years). A shrinking share count, a reverse split where needed, and a demonstrated willingness to deploy capital for shareholders are what institutional investors want to see before they can own the name. The buybacks are as much about the audience as the arithmetic.

Third, it's a quiet vote on rescheduling. Green Thumb, Trulieve and Verano are all sitting on the same information the rest of the market has: an administrative law judge who has closed the record on adult-use, an administration on the record supporting Schedule III, and a Treasury Department that has promised guidance on retroactive 280E relief. A company that expected a bad outcome would hoard cash. Companies that are buying stock at current prices with a 12-month runway are telling you what they think the tax line looks like in 2027.

The one caution

Buybacks only work if the shares are actually cheap and the cash is actually surplus. Green Thumb has earned the benefit of the doubt on both — but $80 million in 2026 is real money for a company whose adjusted EBITDA runs around $85 million a quarter, and M&A opportunities are about to get more interesting as Northeast consolidation and single-state divestitures come to market. Kovler has explicitly kept both doors open. The next twelve months will show whether Green Thumb keeps buying itself or finally buys someone else.

Either way, the signal is the same one the last $200 million sent: the most disciplined operator in the sector thinks its stock is worth more than the market does, and it has been right about that for three years running.

📈 Dog Walkers

$LEEEF ( ▲ 4.89% ) Adds Hirsh Jain to the Board

LEEF Brands (CSE: LEEF) (OTCQB: LEEEF) named Hirsh Jain to its board as an independent director Monday, elevating a strategic advisor who's been working with the California concentrate maker on federal and state policy, interstate commerce and international exports. Kevin Wilson stepped off the board in the same move and stays on as CFO, leaving a five-member board with three independents.

That last detail is the point. LEEF now has fully independent audit and compensation committees and a majority-independent nominating committee — the checklist a company runs through when it's thinking about a U.S. exchange listing. CEO Micah Anderson said as much, framing the changes as building "the governance infrastructure expected of larger U.S. public companies." A CFO who's also a director is fine for the CSE. It's a question mark on Nasdaq.

Jain's résumé fits the moment. He founded Ananda Strategy, a cannabis advisory shop that works with operators on regulatory and licensing strategy, and has spent nine years in the industry, including deep engagement with California's Governor's Office and dozens of local governments since adult-use launched in 2018. Before cannabis he ran government affairs at Airbnb and was an engagement manager at McKinsey; he holds a Harvard J.D. and a Berkeley undergrad. For a company whose thesis is that the walls between cannabis markets are coming down, a policy operator who knows how to work Sacramento is a useful director to have.

The strategic backdrop is what makes this more than a routine board refresh. LEEF has filed DEA registration applications across its California and Nevada licenses and is building relationships in international markets while preparing its operations to meet destination-market standards. Jain's line — that barriers between markets "will increasingly come under pressure" — is the thesis in one sentence. LEEF is positioning to be a California concentrate exporter when the rules allow it, and it just hired the guy who helps write those rules.

$HELP ( ▲ 10.43% ) Unveils New Data

Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP) showed up to Psych Congress in New Orleans with a full wall of data on HLP003, its oral deuterated psilocin analog in development as an adjunctive treatment for major depressive disorder. Four posters, three of them mined from the completed Phase 1/2a study and one previewing the ongoing Phase 3 PARADIGM program.

The Phase 1/2a posters do the work of turning a small trial into a clinical story. One breaks down MADRS results item by item and isolates the anhedonia subscale — the symptom cluster where conventional antidepressants tend to underperform and where psychedelic-class compounds have shown their clearest separation. A second examines how participants actually experienced the psychedelic effect, which matters because a deuterated analog is designed to alter the pharmacokinetics of psilocin and, potentially, the duration and intensity of the dosing session. The third is an expanded safety analysis, the dataset payers and regulators care about most. The headline across all three is the inclusion of 12-month efficacy results, extending the durability argument to a full year.

The PARADIGM poster is the one to watch. A trial-in-progress presentation at a major psychiatry conference is how a company recruits sites, investigators and eventual prescribers before the data exists. With Compass Pathways moving toward an NDA filing this quarter and the FDA publicly framing psychedelics as a priority, Helus is positioning HLP003 as the next-generation entrant: a synthetic, orally dosed, patent-protected molecule with a cleaner pharmacological profile than natural psilocybin. Psych Congress was the right room to make that case.

📺 Trade To Black

Cannabis Stocks: What It Would Take to Gap Up | TTB Presented by Flowhub

• Rescheduling rumors hit the tape: Speculation that ALJ Derek Julius could issue his recommendation this week sparked late-Friday buying that carried into Monday, with Trulieve trading more than 12 million shares Friday afternoon alone.

• Options are stacking up: Pristine Capital's Andrew O'Connell breaks down heavy volume at the $5 strike for September 25 and still-elevated open interest in the October 16 $6 calls.

• What a real catalyst looks like: Historically the sector sees a three-to-ten day window of sustained upside after major news — and we lay out what fundamentals need to line up for a true gap-up.

• Trulieve is the linchpin: Still capped at $13 resistance and roughly 30% of MSOS, and this would be the first rescheduling headline since TRLV and Glass House listed on the NYSE — a different trading setup than any prior cycle.